ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bosentan

Also written as “bosentan”, “Bosentan 125 mg” and “Bosentan 62.5 mg”.

Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Idiopathic Pulmonary Fibrosis · digital ulcers · Scleroderma, Systemic, led by 5 companies.

Drug pageBosentan: every studyMany companies study it; this page follows only the 30 they lead. All 85 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 30, 200430 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson260 open or runningphase 4since Apr 30, 2004Oct 6, 2003none ahead
Geropharmits history only10 open or runningphase 1since Sep 23, 2019Sep 23, 2019none ahead
Hanmi Pharmaceuticalits history only10 open or runningphase 1since May 20, 2013May 20, 2013none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Jun 26, 2024Jun 26, 2024none ahead
Retinset SLits history only10 open or runningphase 1since Aug 22, 2019Aug 22, 2019none ahead

Also a collaborator on its studies: Dong-A ST.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Oct 6, 2003.

  1. Mar 16, 2006Phase 4 study in Pulmonary Arterial HypertensionNCT00303459 · 334 enrolled
  2. Apr 3, 20068 phase 3 studiesNCT00310830, NCT00313222, NCT00313196 and 5 more
  3. Apr 21, 2006Phase 4 study in Pulmonary Arterial HypertensionNCT00317486 · 54 enrolled
  4. Aug 2, 2006Phase 3 study in Hypertension, PulmonaryNCT00360087 · 236 enrolled
  5. Aug 21, 2006Phase 4 study in Pulmonary Arterial HypertensionNCT00367770 · 37 enrolled · United States, Australia, Austria and more
  6. Oct 20, 2006Phase 3 study in Idiopathic Pulmonary FibrosisNCT00391443 · 616 enrolled
  7. Feb 7, 2007Phase 4 study in Pulmonary Arterial HypertensionNCT00433329 · 100 enrolled
  8. Jan 7, 2008Phase 4 study in Hypertension, PulmonaryNCT00595049 · 11 enrolled · Australia
  9. Feb 12, 2008Phase 3 study in Idiopathic Pulmonary FibrosisNCT00631475 · 128 enrolled
  10. Oct 14, 2009Phase 2 study in MelanomaNCT01009177 · 80 enrolled · Australia
  11. Oct 12, 2010Phase 3 study in Pulmonary Arterial HypertensionNCT01223352 · 64 enrolled
  12. Apr 15, 2011Phase 3 study in Pulmonary Arterial HypertensionNCT01338415 · 58 enrolled · United States, Australia, Belarus and more
  13. Jun 30, 2011Phase 3 study in Persistent Fetal Circulation SyndromeNCT01389856 · 23 enrolled
  14. Jul 6, 2011Phase 4 study in Scleroderma, SystemicNCT01395732 · 18 enrolled · Netherlands

TargetBeta

EDNRA →EDNRB →read by rule
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
aprocitentanruleIdorsia Pharmaceuticalsphase 314

Studies

All 26 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01395732Scleroderma, Systemic · Netherlands4CompletedNov 30, 201218
NCT01389856Persistent Fetal Circulation Syndrome3TerminatedDec 201323
NCT01338415Pulmonary Arterial Hypertension · United States, Australia, Belarus and more3CompletedAug 13, 201458
NCT01223352Pulmonary Arterial Hypertension3CompletedApr 3, 201364
NCT01009177Melanoma · Australia2CompletedFeb 29, 200880
NCT00631475Idiopathic Pulmonary Fibrosis3CompletedApr 2010128
NCT00595049Hypertension, Pulmonary · Australia4CompletedDec 31, 200811
NCT00433329Pulmonary Arterial Hypertension4CompletedMay 2010100
NCT00391443Idiopathic Pulmonary Fibrosis3CompletedFeb 2010616
NCT00367770Pulmonary Arterial Hypertension · United States, Australia, Austria and more4CompletedDec 200537
NCT00360087Hypertension, Pulmonary3TerminatedAug 2007236
NCT00319696digital ulcers3CompletedJan 22, 2009116
NCT00319267Pulmonary Arterial Hypertension3CompletedDec 200636
NCT00319111Hypertension, Pulmonary3CompletedFeb 2009151
NCT00319033Lung Diseases, Interstitial3CompletedFeb 2006132
NCT00319020Pulmonary Arterial Hypertension3CompletedOct 28, 201133
NCT00317486Pulmonary Arterial Hypertension4CompletedApr 200554
NCT00313222Chronic Thromboembolic Pulmonary Hypertension3CompletedFeb 2007157
NCT00313196Hypertension, Pulmonary3TerminatedAug 200712
NCT00310830Hypertension, Pulmonary3TerminatedAug 200714
NCT00303459Pulmonary Arterial Hypertension4CompletedDec 2013334
NCT00091715Hypertension, Pulmonary · United States, Australia, Austria and more3CompletedNov 2006185
NCT00082186Hypertension, Pulmonary4CompletedFeb 200722
NCT00077584digital ulcers3CompletedMar 2005188
NCT00071461Idiopathic Pulmonary Fibrosis · United States, Canada, France and more3CompletedSep 2005158
NCT00070590Pulmonary Fibrosis3CompletedSep 2005132

How it is read

Names in the registry

  • “Bosentan”, 19 entries
  • “bosentan”, 12 entries
  • “Bosentan 125 mg”, 3 entries
  • “Bosentan 62.5 mg”, 2 entries
  • “Bosentan Dispersible Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.